ECP
ARIA

Elk Creek Partners’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Elk Creek Partners’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-543,063
Closed -$6.76M – 165
2016
Q4 		$6.76M Sell
543,063
-343,498
-39% -$4.14M 0.46% 88
2016
Q3 		$12.1M Sell
886,561
-1,165,964
-57% -$11.7M 0.8% 52
2016
Q2 		$15.2M Buy
2,052,525
+300,712
+17% +$2.26M 1.08% 30
2016
Q1 		$11.2M Buy
1,751,813
+159,286
+10% +$893K 0.83% 48
2015
Q4 		$9.95M Buy
1,592,527
+244,332
+18% +$1.6M 0.71% 56
2015
Q3 		$7.87M Buy
1,348,195
+100,278
+8% +$773K 0.64% 60
2015
Q2 		$10.3M Buy
1,247,917
+219,654
+21% +$1.94M 0.93% 34
2015
Q1 		$8.47M Sell
1,028,263
-124,203
-11% -$918K 0.88% 35
2014
Q4 		$7.92M Buy
1,152,466
+493,234
+75% +$3.08M 1.02% 24
2014
Q3 		$3.56M Buy
659,232
+31,264
+5% +$183K 0.93% 47
2014
Q2 		$4M Buy
627,968
+337,082
+116% +$2.32M 1.09% 34
2014
Q1 		$2.35M Buy
290,886
+98,921
+52% +$770K 1.01% 43
2013
Q4 		$1.31M Buy
+191,965
New +$1.04M 0.94% 44

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Elk Creek Partners's ARIA Position: Q1 2017 in Review

Elk Creek Partners sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 543,063 shares — an estimated $6.76M sold.

Elk Creek Partners first reported a position in ARIA in Q4 2013 and held it in 13 quarters. The position peaked at $15.2M in Q2 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Elk Creek Partners reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Elk Creek Partners sold 543,063 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $6.76M.
  • Elk Creek Partners first reported a position in Ariad Pharmaceuticals Inc in Q4 2013 and held it in 13 quarters.
  • Elk Creek Partners's Ariad Pharmaceuticals Inc position peaked at $15.2M in Q2 2016.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Elk Creek Partners's 13F filing for Q1 2017, filed 12 May 2017.